{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:19:55Z","timestamp":1761963595210,"version":"build-2065373602"},"reference-count":15,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T00:00:00Z","timestamp":1300147200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>Sclerodermatous graft\u2010versus\u2010host disease (sGVHD) is a rare, late complication of hematopoietic cell transplantation. Classified as a variant of chronic graft\u2010versus\u2010host disease, sGVHD is thought to be predominantly an immune\u2010mediated response characterized by aberrant T\u2010cell function and dysregulation of tyrosine kinase cascades. Recently, the profibrotic cytokine transforming growth factor B and stimulatory autoantibodies against the platelet\u2010derived growth factor receptor have been implicated in the pathogenesis of sGVHD. Treatment of sGVHD remains disappointing and largely limited by systemic side effects. Imatinib mesylate is a small molecule tyrosine kinase inhibitor that has been shown to selectively inhibit both the platelet\u2010derived growth factor receptor and transforming growth factor\u2010\u03b2 signaling pathways. We report a case of sGVHD in a pediatric patient that was resistant to traditional therapy but showed improvement in cutaneous symptoms following daily treatment with 400\u2003mg of imatinib mesylate. Due to its favorable side\u2010effect profile, specificity for molecular pathways deranged in sGVHD and proven efficacy in other sclerodermoid diseases, imatinib mesylate is a promising new tool in the management of this challenging disease.<\/jats:p>","DOI":"10.1111\/j.1525-1470.2010.01301.x","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T02:16:03Z","timestamp":1300241763000},"page":"172-175","source":"Crossref","is-referenced-by-count":11,"title":["A Case of Sclerodermatous Graft\u2010versus\u2010Host Disease Responsive to Imatinib Therapy"],"prefix":"10.1111","volume":"28","author":[{"given":"Jozef","family":"Lazar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tasneem","family":"Poonawalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce M.C.","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2231"},{"key":"e_1_2_4_3_2","first-page":"258","article-title":"Sclerodermatous chronic graft\u2010versus\u2010host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome","volume":"91","author":"Skert C","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07827.x"},{"key":"e_1_2_4_5_2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archderm.144.9.1106","article-title":"Imatinib as a potential treatment for sclerodermatous chronic graft\u2010vs\u2010host disease","volume":"144","author":"Moreno\u2010Romero JA","year":"2008","journal-title":"Arch Dermatol"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-071043"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052955"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.06.001"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01211.x"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.08.029"},{"key":"e_1_2_4_11_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","article-title":"Abl protein\u2010tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c\u2010kit and platelet\u2010derived growth factor receptors","volume":"295","author":"Buchdunger E","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23698"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22314"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441401"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra013339"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1446"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1470.2010.01301.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-1470.2010.01301.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:42:26Z","timestamp":1741099346000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-1470.2010.01301.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1525-1470.2010.01301.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1470.2010.01301.x","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"type":"print","value":"0736-8046"},{"type":"electronic","value":"1525-1470"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}